Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles, mumps, and rubella virus vaccine live (Merck & Co., 7df7b7)
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
M-M-R II is a live attenuated trivalent viral vaccine developed and manufactured by Merck for active immunization against measles, mumps, and rubella. It contains weakened forms of three viruses: the measles virus (Enders' attenuated Edmonston strain, propagated in chick embryo cell culture), the mumps virus (Jeryl Lynn B-level strain, propagated in chick embryo cell culture), and the rubella virus (Wistar RA 27/3 strain, propagated in WI-38 human diploid lung fibroblasts). The vaccine is indicated for individuals 12 months of age or older, typically administered in a two-dose schedule (first dose at 12–15 months and second dose at 4–6 years). It stimulates both humoral and cellular immune responses, leading to the production of protective antibodies against the three target viruses.
- Brand names
- M-M-R IIM-M-RvaxPro
- Other names
- MMR vaccinemeasles, mumps and rubella vaccine (live)
02
Targets
RUBV C (Rubella virus capsid protein)
Beyond the preview
Go deeper on measles, mumps, and rubella virus vaccine live (Merck & Co., 7df7b7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles, mumps, and rubella virus vaccine live (Merck & Co., 7df7b7).